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ORIGINAL RESEARCH
Aim: To explore the relationship between actual and expected general medical practitioner
(GP) practice prescribing rates for statins, angiotensin converting enzyme (ACE) inhibitors,
and beta-blockers.
Background: There is a growing body of literature highlighting inequities in GP practice
prescribing rates for many drug therapies. The equity of prescribing is of central importance
in the area of therapeutics since it explores the interface between those patients who should
and those who actually do receive a drug therapy.
Setting: Four primary care trusts (PCTs 1–4) in the North West of England, including 132
GP practices.
Methods: Actual and expected prescribing rates for statins, beta-blockers, and ACE inhibitors
were specifically developed for each GP practice.
Results: There were no statistically significant correlations between actual and expected
prescribing rates in PCT2 and PCT3, although in PCT1 there were statistically significant
correlations for statins (0.286, p < 0.05) and ACE inhibitors (0.381, p < 0.01). In PCT4,
correlations were moderate to high for beta-blockers (0.693, p < 0.01), and moderate for statins
(0.541, p < 0.05) and ACE inhibitors (0.585, p < 0.01). Scatterplots highlighted large variations
between individual GP practices (both within and between PCTs) in terms of the relationship
between actual and expected prescribing rates.
Conclusion: This paper highlights variability between PCTs and GP practices in terms of
the relationship between actual and expected prescribing rates. The findings from this paper
may further advance the suggestion of inequities in prescribing rates for coronary heart disease
(CHD) drugs, and studies such as this may be repeated in different therapeutic areas, healthcare
settings, and countries.
Keywords: prescribing rates, equity, coronary heart disease, statins, beta-blockers, ACE
inhibitor
Introduction
The overriding aim of this paper is to explore the relationship between actual and
expected general medical practitioner (GP) practice prescribing rates for statins,
angiotensin converting enzyme (ACE) inhibitors, and beta-blockers. These drug
groups were chosen because they represent major drug groups recommended for the
prevention (primary and secondary) of coronary heart disease (CHD) in the United
Kingdom (UK) (Department of Health 2000). Other CHD drug groups were also
explored in the main study, although data are only available to calculate expected
prescribing rates for these three drug groups.
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The actual prescribing rates are based on 1999–2000
prescribing data from 132 GP practices in the North West
of England. The expected prescribing rates were calculated
from age-sex prescribing rates for these drugs collected in
the General Practice Research Database (GPRD), which
have been applied to the age-sex patient list data for the GP
practices in this study. One may expect a positive
relationship between actual and expected prescribing rates,
and large deviations from this (ie, high actual and low
expected prescribing rates, or low actual and high expected
prescribing rates) may be suggestive of inequitable
prescribing rates. Although expected prescribing rates are
indicative of healthcare supply and/or demand, as opposed
to solely healthcare need, they are used in this paper to
explore how GP practice prescribing rates differ from what
we may expect given the age-sex composition of their patient
population.
Separate papers by the authors based on the same study
have found inequitable prescribing rates for aspirin, statins,
ACE inhibitors, beta blockers, and bendrofluazide (Ward et
al 2003, 2004a, 2004b). These papers examined and modeled
the associations between actual prescribing rates and
indicators of healthcare need, and found inequities on the
basis of patient age, ethnicity, and deprivation. In other
words, prescribing rates were generally higher in GP
practices with lower proportions of patients aged over 75
years, lower proportions of minority ethnic patients, and
lower proportions of deprived patients. The current paper
explores the separate issue of the association between actual
prescribing rates and expected prescribing rates calculated
from data in the GPRD, standardized for the age-sex
composition of each GP practice. The equity of prescribing
rates are explored from a different perspective, using
expected prescribing rates rather than indicators of
healthcare need.
The importance of equity in the
world of therapeutics
One of the most important principles of healthcare systems
in the developed world is based around the notion of equity.
Within the UK, the National Health Service (NHS) was set
up to provide a universal entitlement to the same quality of
healthcare services solely on the basis of clinical need (Le
Grand 1982; Goddard and Smith 2001). There are large
literatures on how to define, operationalize, and measure
equity in relation to healthcare services, although equity is
generally taken to mean “fair” or “just”.
The concept of equity of prescribing is extremely
important in the area of therapeutics, since it informs us of
the groups of patients who are currently receiving these drug
therapies (and maybe do not need the drugs) and those who
are currently not receiving these drug therapies (and maybe
do need the drugs). There is a sound evidence base in terms
of the effectiveness of drug therapies and which patients
may benefit from statins (Byington et al 1995; Shepherd et
al 1995; Sacks et al 1996; Ebrahim et al 1998; Pignone et al
2000), ACE inhibitors (Eccles et al 1998; Blood Pressure
Lowering Treatment Trialists’ Collaboration 2000; Yusuf et
al 2000), and beta-blockers (MacMahon et al 1997; Gottlieb
et al 1998; Julian 1998; Mehta and Eagle 1998), although
our evidence base in terms of who actually receives the drugs
in practice is less well developed. Obviously, it is also crucial
to understand which patients benefit from the drugs,
however, this is not within the remit of this paper. Here, we
look at the interface between who could benefit (eg, older
populations, South Asian populations, deprived populations,
populations with a high prevalence of CHD and/or high
mortality rates from CHD) and who actually receives the
drugs.
Another way to think about equity is the relationship
between healthcare provision and need. On an individual
level, a healthcare service would be seen as equitable if it
were provided to people with clinical need (and not provided
to those with no (or lower) clinical need). In the context of
research on prescribing, this would require data for
individual patients in terms of drugs prescribed,
sociodemographics, medical history, etc. Within the UK,
there are no nationally available datasets with these types
of data; therefore, research on the equity of prescribing is
generally conducted at population (ecological) level. In this
way, research attempting to assess the equity of prescribing
would explore the relationship between prescribing rates
within a defined population and their concomitant healthcare
needs. Equity would be explored by comparing different
populations with similar prescribing rates and assessing the
extent to which their healthcare needs were similar. This is
akin to comparative need, which is a domain in the taxonomy
of need (Bradshaw 1972, 1994). One may expect that
prescribing rates would be higher in populations with high
levels of healthcare need and lower in populations with low
levels of healthcare need. Therefore, research that explores
the relationship between prescribing rates and healthcare
need in defined populations will be important in terms of
understanding the equity of healthcare.Therapeutics and Clinical Risk Management 2005:1(1) 63
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Literature on the equity of GP
practice prescribing rates
There is a growing body of research that has highlighted
large variations in overall prescribing rates between GP
practices that are partially explained by factors other than
healthcare need (Morton-Jones and Pringle 1993; Pringle
and Morton-Jones 1994; Majeed et al 1996; Rice et al 2000;
Lloyd and Scrivener 2001). Whilst there have been a number
of studies that have highlighted large variations in statin
prescribing rates between GP practices (Baxter 1998;
Majeed et al 2000), only a limited number have gone on to
explore the equity of this variation (Bradshaw et al 1999;
Majeed et al 2000; Packham et al 2000; Patel et al 2002;
Ward et al 2003, 2004a). These studies suggest inequities
in prescribing rates on the basis of mortality and morbidity
and also on the basis of patient demographics, ethnicity,
and socioeconomic status. Indeed, a previous paper by the
authors of this paper found that prescribing rates for a
number of CHD drugs were negatively associated with a
number of proxies of healthcare need, namely, the proportion
of patients aged over 75 years, ethnicity, levels of material
deprivation, and standardized mortality ratios (SMRs) for
CHD (Ward et al 2004a). In other words, GP practices with
high rates of CHD mortality, higher proportions of patients
aged over 75 years, ethnic minority patients, and materially
deprived patients had lower prescribing rates than GP
practices with lower mortality rates for CHD, younger
patients, less ethnic minority patients, and more affluent
patients. Given that each of these variables indicate higher
risk of CHD in populations, one may infer that prescribing
rates seem to be inequitable and that prescribing in these
GP practices confirms the “inverse care law” (Hart 1971).
The findings from this paper may further advance the
suggestions of inequities in prescribing rates for CHD drugs,
and studies such as this may be repeated in different
therapeutic areas, in different healthcare settings, and in
different countries.
Context and setting
The planning and provision of healthcare to local
populations in England is now the role of primary care trusts
(PCTs). Essentially, PCTs are organizations whose main
responsibilities are around developing, commissioning, and
providing services that are targeted to the needs of local
people and ultimately aimed at improving the health (and
reducing health inequalities) of local people (Department
of Health 1998, 1999). PCTs have taken over these
responsibilities from health authorities, which no longer
exist (Department of Health 2002), and are responsible for
spending 75% of the overall NHS budget in England
(Peckham and Taylor 2003).
This study was undertaken in 4 PCTs in England
(referred to as PCT1, PCT2, PCT3, and PCT4 throughout
this paper), which included 132 GP practices (PCT1 had 50
GP practices, PCT2 24, PCT3 31, and PCT4 27). In terms
of patient populations, we excluded patients aged less than
35 years, since prevalence of CHD is particularly low in
this age group. In total, there were 353 897 registered
patients aged over 35 across all 4 PCTs, and the median list
size was 2297 patients aged over 35.
PCT4 was the most deprived of all PCTs and had the
highest proportion of patients aged over 75 years and the
highest median SMR for CHD. Therefore, PCT4 may be
seen as having the highest levels of healthcare need in terms
of CHD prescribing. In contrast, PCT1 may be seen as
having the lowest levels of healthcare need of all PCTs on
the basis of the healthcare needs indicators developed in
this study. PCT1 was the least deprived, had the lowest
proportions of South Asian groups, and had the lowest
median SMR for CHD. However, PCT1 had the highest
median percentage of patients aged between 55 and 74 years,
which may well be the target age-group for prescribing
within CHD. PCT2 and PCT3 were generally in the middle
of the other PCTs in terms of healthcare need for CHD drugs.
Data sources and methods
This paper is focussed on the association between actual
and expected prescribing rates. This section will focus on
the data sources and methods for developing these
prescribing rates for statins, beta-blockers, and ACE
inhibitors. Local Research Ethics Committee approval was
sought and granted for this study.
Developing actual prescribing rates
When an NHS prescription is dispensed in primary care,
the prescription form (FP10) is sent to the Prescription
Pricing Authority (PPA) for processing. The PPA collates
these data and provides them to GP practices and PCTs in
the form of Prescribing Analysis and Cost (PACT) data.
PACT data are available for all GP practices in England and
allow detailed interrogation in terms of drugs prescribed
along with their dosages, pack sizes, and formulations. For
example, for a specific time period, we can collect data on
which statins were prescribed by a GP practice in additionTherapeutics and Clinical Risk Management 2005:1(1) 64
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to the dosages and pack sizes. This allows for a complex
and timely analysis of PACT data. Useful critiques of PACT
data can be found elsewhere (Majeed et al 1997; Chapman
2001).
PACT data were obtained for a number of CHD drugs
prescribed in all GP practices in the 4 PCTs for the 12-
month period October 1999 to September 2000. This paper
is based on prescribing for statins (atorvastatin, cerivastatin,
fluvastatin, pravastatin, simvastatin), ACE inhibitors
(captopril, enalapril, lisinopril, ramipril, trandolapril), and
beta-blockers (atenolol, co-tenidone). All statins available
to prescribe on the NHS at the time of the study were
included in the study, although cerivastatin was withdrawn
from use in the UK in 2001. The category of ACE inhibitor
drugs is not exhaustive, although the five drugs used
represented the vast majority of prescribing of all ACE
inhibitors in the study GP practices. Atenolol represented
over 80% of all beta-blocker prescribing in the study GP
practices, although prescribing advisers suggested that we
also include co-tenidone, which is a combinational product
including atenolol and chlorthalidone (a diuretic) and is
therefore not strictly just a beta-blocker. Nevertheless, the
PACT data collected represents all statin prescribing and
the vast majority of ACE inhibitor and beta-blocker
prescribing.
The numerator in all prescribing rates was based on a
measure of prescription volume, as opposed to prescription
cost. The validity of using the number of prescription items
or total cost as a measure of prescribing volume has been
called into question (Bogle and Harris 1994; Frischer and
Chapman 1998) since it does not specify the quantity of
prescription medication (eg, number and/or dosage of
tablets). Therefore, a measure of prescription volume which
calculates the total number of grams prescribed is much
more useful. The main options available are defined daily
doses (DDDs) (WHO 1991; PSU 1997) and average daily
quantities (ADQs) (PSU 1997; PSU 2000; Walley and
Roberts 2000). The Prescribing Support Unit website
provides up-to-date lists of DDDs and ADQs
(www.psu.co.uk) for all drugs for which they have been
developed. Within this study, total ADQs were used as the
unit of analysis since they represent prescribing practices
in the UK, as opposed to DDDs, which represent prescribing
practices internationally. The Prescribing Support Unit state
that an ADQ “should not be viewed as a suggested dosage,
but rather as an analytical unit for comparing prescribing
performance” (PSU 2002, p 9).
The denominator in prescribing rates was the regionally
specific prevalence-, age-, and sex-standardized prescribing
units (PASS-PUs). PASS-PUs were developed within this
study and represent the age-sex standardized expected
prevalence of treated CHD in each GP practice population
(see Table 1) (ONS 1998b).
Basically, PASS-PUs are calculated using data from GP
practice lists on the age-sex composition of their registered
patients and then applying the age-sex rates of treated CHD
prevalence data to the practice list data. In so doing, we
calculated the expected rates of treated CHD in all GP
practices in the study. (See Ward et al 2003 for a full
discussion and critique of PASS-PUs.) We found that using
PASS-PUs as the denominator in prescribing rates was better
than just using total list size, since this did not reflect the
age-sex composition of the patients or their expected rates
of CHD. In addition, we also found that PASS-PUs were
better than other widely used prescribing units such as
specific therapeutic group age-sex–related prescribing units
(STAR-PUs) (Lloyd et al 1995; PSU 2000) since these are
based on historical, cost-based prescribing patterns which
may not reflect CHD prevalence.
Overall, the prescribing rate used in this study was total
ADQs prescribed per PASS-PU.
Developing expected prescribing rates
Data were collected in the General Practice Research
Database (GPRD) on age-sex rates of prescribing for statins,
beta-blockers, and ACE inhibitors. The GPRD derives data
from a representative sample of GP practices in England
(211 GP practices with a combined population of around
1.4 million patients) about the NHS care received by their
registered patients (ONS 1998a). This group of GP practices
regularly collects data for the GPRD. The age-sex rates of
prescribing per 1000 patients are presented in Table 2.
From the data in Table 2, expected prescribing rates were
calculated separately for statins, beta-blockers, and ACE
inhibitors. The age-sex specific rates in the above table were
applied to the same age-sex groups within the registered
patient populations of all GP practices in the study. For
Table 1 Prevalence of treated CHD per 1000 patients by age
and sex
0–34 35–44 45–54 55–64 65–74 75–84 85+
Male 0.1 5 29 93.4 175.1 216.8 205.3
Female 0.1 1.8 12.6 48.3 108.1 161.6 171.7
Source: Office for National Statistics (1998b).Therapeutics and Clinical Risk Management 2005:1(1) 65
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example, to calculate the expected rate of statin prescribing
for a GP practice, the total number of registered patients in
each of the age-sex groups was multiplied by the
corresponding rate of prescribing for that age-sex group.
The individual age-sex expected rates were then summed
and divided by the total number of PASS-PUs. In this way,
an expected rate of statin prescribing was calculated based
on the demographics of the GP practice registered
population. In addition, both the actual and expected
prescribing rates had the same denominator (PASS-PUs).
These calculations were undertaken for the three drug groups
across all GP practices in the study.
Data analysis
Associations between actual and expected prescribing rates
were calculated using correlation coefficients. They are
presented graphically using scatterplots. Univariate analysis
revealed that some prescribing rates exhibited a non-
parametric distribution, with some GP practices having
either particularly high or particularly low prescribing rates.
Therefore, the Spearman Rank correlation coefficient was
calculated (as opposed to the Pearson Product Moment
correlation coefficient) since it does not rely on normally
distributed data and is not influenced by outlying data points.
Results
Table 3 presents the correlation coefficients between the
actual and expected prescribing rates. Results are presented
for each PCT, in addition to the overall dataset. In PCT2
and PCT3, none of the correlations between actual and
expected prescribing rates were statistically significant. In
PCT1, there were statistically significant correlations for
statins and ACE inhibitors; and in PCT4 and the combined
dataset, all associations were statistically significant. The
results suggest that prescribing rates in PCT4 are the most
closely associated with expected prescribing rates, followed
by prescribing rates for statins and ACE inhibitors in PCT1.
The association between actual and expected prescribing
rates for beta-blockers in PCT4 was moderate to high (0.693,
p < 0.01), and those for statins and ACE inhibitors were
moderate (0.541, p < 0.05 and 0.585, p < 0.01, respectively).
In the combined dataset, statins and ACE inhibitors had
moderate correlation coefficients (around 0.5, p < 0.01),
although beta-blockers had a low coefficient (0.259,
p < 0.01).
The results in Table 3 are useful in terms of general
associations between actual and expected prescribing rates,
although scatterplots help us to identify individual GP
practices that seem to be either prescribing higher or lower
rates than may be expected. In addition, the scatterplots
allow us to visualize the differences between PCTs, which
cannot be seen in the correlation coefficients.
Figure 1 presents a scatterplot of actual and expected
prescribing rates for statins, whereby each marker on the
graph is an individual GP practice. In order that differences
or similarities between PCTs can be identified, each GP
practice has been marked with their respective PCT.
The correlation coefficient suggested a modest, positive
association, which can be seen on the scatterplot. However,
Table 2 Age-sex prescribing rates for specific CHD drug
groups
Drug group 35–44 45–54 55–64 65–74 75–84 85+
Statins M 6.1 26.0 56.7 67.5 25.5 2.6
F 2.0 10.4 38.5 57.0 21.6 2.4
Beta blockers M 20.9 55.6 103.5 139.3 119.4 54.4
F 30.0 63.5 108.6 152.0 146.4 73.6
ACE inhibitors M 11.3 40.4 94.4 149.9 170.3 134.6
F 8.0 31.0 72.7 122.0 151.3 117.5
Source: Office for National Statistics (1998a).
Table 3 Correlations between actual and expected prescribing
rates
Drug group PCT1 PCT2 PCT3 PCT4 Combined
Statins 0.286* –0.196 0.096 0.541* 0.498**
ACE inhibitors 0.381** –0.073 0.017 0.585** 0.484**
Beta-blockers 0.079 0.146 0.075 0.693** 0.259**
NOTE: ** correlation significant at 0.01 level, * correlation significant at 0.05 level.
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Figure 1 Scatterplot of actual and expected prescribing rates for statins.Therapeutics and Clinical Risk Management 2005:1(1) 66
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the scatterplot reveals large differences between PCT4 and
the other PCTs, and also between individual GP practices
within PCTs. For example, in PCT3, there is an almost
7-fold difference in actual prescribing rates between GP
practices, although the difference in expected prescribing
rates is less than 3-fold. In PCT4, the majority of GP
practices are located in the bottom left-hand corner of the
graph (low actual and expected prescribing rates) although
there are 3 outlying GP practices which seem to be quite
different. Two of these GP practices are located amongst
GP practices in the other PCTs and another is located on its
own, with a suggestion of a relatively high actual prescribing
rate in comparison to its expected prescribing rate. If one
were to draw a vertical line on the scatterplot, there would
be a number of GP practices with the same actual prescribing
rate, although the expected prescribing rates would differ
markedly.
Figures 2 and 3 present similar patterns to Figure 1,
whereby GP practices in PCT4 are generally situated at the
bottom left-hand corner of the graphs (with a few
exceptions), which suggests that they have lower actual and
expected prescribing rates for ACE inhibitors and beta-
blockers than GP practices in the other PCTs. However, the
actual prescribing rates of many GP practices in PCT4 are
similar to many of those in the other PCTs, although the
expected prescribing rates in the other PCTs tend to be much
higher. Again, one could draw a vertical line on both
scatterplots and identify GP practices with similar actual
prescribing rates but vastly differing expected prescribing
rates. The main message to take from all three scatterplots
relates to the variability between GP practices in the
association between actual and expected prescribing rates.
Discussion and conclusions
Main strengths
First, the study was based on all GP practices in 4 PCTs,
rather than a random sample such as those in the GPRD.
Therefore, the results are directly applicable to the PCTs
and enable them to develop local policies/guidance without
the need to infer from GP practices in other areas. Second,
we used prescribing rates based on ADQs, which are more
applicable to UK general practice, and also based on the
expected prevalence of treated CHD (PASS-PUs). As
already stated, international comparisons may wish to use
DDDs. Third, we developed expected prescribing rates for
all GP practices which may be used by the PCTs to audit
changes in the equity of prescribing rates over time. Finally,
we produced scatterplots which enable the identification of
individual GP practices which seem to either have higher
or lower actual than expected prescribing rates. Further work
could then be undertaken within these GP practices to
understand the reasons behind their apparent inequitable
prescribing rates, and subsequently, to provide education
and support to make their prescribing rates more equitable.
Main weaknesses
First, ecological analysis cannot be used to infer causal
relationships or to infer similar relationships at an individual
Figure 2 Scatterplot of actual and expected prescribing rates for ACE
inhibitors.
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Figure 3 Scatterplot of actual and expected prescribing rates for beta-
blockers.
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level (the ecological fallacy). Second, PACT data refer only
to NHS scripts that have been dispensed at pharmacies,
rather than all prescriptions issued by GPs. Third, the data
on statin prescribing rates is based on 1999–2000 data, which
may be slightly out of date given the recent increases in
statin prescribing. However, we have no evidence that this
increase has increased the equity of prescribing rates, since
it may have increased at a similar rate across all GP practices.
Nevertheless, it may be useful to provide data for 2003–2004
to confirm or reject this. An update of prescribing data would
also be useful for ACE inhibitors and beta-blockers. Fourth,
the data used to develop the expected prescribing rates may
not necessarily equate to healthcare need, since prescribing
is also influenced by supply and demand elements.
Nevertheless, the age-sex prescribing rates are similar to
the age-sex rates of treated CHD (see Table 1) and therefore
may reflect the demographic nature of CHD. However, even
though age seems to be the most important risk factor for
CHD (Tunstall-Pedoe et al 1999), these do not take into
account the multifactorial nature of CHD risk factors and
therefore do not reflect the totality of CHD healthcare needs.
Key points
To our knowledge, this is the first paper reporting
associations between actual and expected prescribing rates,
and as such, our findings represent new ground in the
exploration of the equity of prescribing rates. This paper
explored the relationship between actual and expected GP
practice prescribing rates for statins, ACE inhibitors, and
beta-blockers. In the combined dataset, there was a
moderately strong positive correlation (p < 0.01) for statins
and ACE inhibitors, and a weaker correlation for beta-
blockers (p < 0.01). Within the individual PCTs, there was
a large degree of variation. In PCT4, there were moderate
to fairly high correlations (p < 0.05) for all three drug groups,
although in PCT2 and PCT3 there were no statistically
significant associations for any drug groups. In PCT1, there
were fairly low correlations (p < 0.05) for statins and ACE
inhibitors, although beta-blockers exhibited no association.
Therefore, from these findings, we can observe variability
between PCTs in terms of the relationship between actual
and expected prescribing rates. Increasing rates of actual
prescribing are associated with increasing rates of expected
prescribing in PCT4, the combined dataset and (to a lesser
extent) in PCT1, although this is not the case in PCT2 and
PCT3. Therefore, this may be suggestive of inequities in
prescribing rates in PCT2 and PCT3, since one would expect
higher correlations between actual and expected prescribing
rates in these PCTs.
The issue of variability is made even more apparent in
the scatterplots, both between PCTs and between individual
GP practices. GP practices in PCT4 tended to be located in
the bottom left-hand corner of the scatterplots, which
indicates lower rates of actual and expected prescribing,
whereas GP practices in the other PCTs seemed to be
intermingled into a general “cloud” of data points. One of
the main purposes of producing the scatterplots was to
highlight the point that one could draw a vertical line almost
anywhere on the graphs and locate GP practices with very
similar actual prescribing rates but vastly different expected
prescribing rates. Since the expected prescribing rates are
calculated from data which exhibit similar patterns to age-
sex CHD prevalence data, this may be suggestive of
inequities in prescribing rates.
Whilst the clinical and epidemiological data on statins,
beta-blockers, and ACE inhibitors has allowed for the
development of evidence-based guidelines and evidence-
based prescribing, this paper suggests that in practice, actual
prescribing rates may not be related to healthcare need.
Further research needs to concentrate on verifying or
falsifying these claims on a more micro-level analysis (eg,
clinical audit in specific GP practices identified in the study)
and on exploring the reasons why such a relationship exists
(eg, qualitative studies with GPs, practice nurses, and
patients in the identified GP practices). This strategy may
enable educational tools to be developed that would facilitate
more evidence-based prescribing, but may also identify
particular patient groups who do not present symptoms of
CHD (ie, unmet need) and therefore may require educational
outreach or targeted screening to increase their consultations
and ultimately prescribing to these groups. Although we
have focussed on three drugs for the prevention of CHD,
a similar approach may be taken in any number of
therapeutic areas to explore the equity of prescribing or other
healthcare services.
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